HC Wainwright Has Lowered Expectations for Carisma Therapeutics (NASDAQ:CARM) Stock Price

Carisma Therapeutics (NASDAQ:CARM) had its target price lowered by HC Wainwright from $8.00 to $5.00 in a report issued on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Carisma Therapeutics’ FY2024 earnings at ($1.32) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.00) EPS.

Separately, EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th.

Carisma Therapeutics Price Performance

NASDAQ:CARM opened at $0.84 on Monday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The business’s 50-day moving average price is $0.96 and its 200 day moving average price is $1.09. Carisma Therapeutics has a 52-week low of $0.80 and a 52-week high of $3.16. The firm has a market cap of $35.11 million, a P/E ratio of -0.54 and a beta of 1.49.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The firm had revenue of $3.39 million for the quarter. As a group, sell-side analysts predict that Carisma Therapeutics will post -1.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Carisma Therapeutics

A number of institutional investors have recently bought and sold shares of CARM. Barclays PLC lifted its position in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Carisma Therapeutics in the second quarter worth $40,000. Wexford Capital LP raised its holdings in shares of Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Carisma Therapeutics by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after purchasing an additional 11,200 shares during the last quarter. 44.27% of the stock is currently owned by institutional investors and hedge funds.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.